Neuropace Inc (NPCE)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $260.45M
Last updated: Nov 17, 2026 at 11:05 AM ET
Neuropace Inc (NPCE) Stock Forecast
Analysts expect Neuropace (NPCE) to earn -$0.41 per share in the fiscal year ending Dec 31, 2026, on revenue of $99.26M. Of 10 analysts, 10 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 7 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 1.90, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 10.0% |
| Buy | 9 | 90.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 21.4%.
- Fiscal year ending Dec 31, 2026
- -$0.41
- EPS consensus, revenue $99.26M
- Fiscal year ending Dec 31, 2027
- -$0.19
- EPS consensus, revenue $120.48M
- Next report
- Mar 1, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.41 | -$0.67 to -$0.35 | 8 | $99.26M | $91.60M to $101.10M | 9 |
| Dec 31, 2027 | -$0.19 | -$0.38 to $0.09 | 8 | $120.48M | $104.00M to $125.20M | 10 |
Quarterly Estimates
The EPS consensus rises from -$0.09 for the quarter ending Dec 31, 2026 to -$0.08 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.09 | -$0.14 to -$0.04 | 12 | $25.33M | $22.54M to $30.49M | 12 |
| Mar 31, 2027 | -$0.08 | -$0.12 to -$0.04 | 3 | $26.72M | $26.10M to $27.00M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 12 upward and 3 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 7 | 0 |
| Fiscal year ending Dec 31, 2027 | 4 | 3 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.45.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.41 | -$0.41 | -$0.41 | -$0.41 | -$0.45 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.19 | -$0.19 | -$0.19 | -$0.19 | -$0.22 | N/A |
| Quarter ending Mar 31, 2027 | -$0.08 | -$0.11 | -$0.11 | -$0.11 | -$0.11 | N/A |
Frequently Asked Questions About NPCE
What is the NPCE stock forecast?
Consensus analyst estimates put Neuropace's EPS at -$0.41 for the fiscal year ending Dec 31, 2026, on revenue of $99.26M. The consensus rating from 10 analysts is Buy.
How do analysts rate NPCE stock?
Of 10 analysts covering Neuropace, 1 rates it Strong Buy, 9 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NPCE next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.41, with estimates from -$0.67 to -$0.35 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.19, with estimates from -$0.38 to $0.09 from 8 analysts.
What revenue do analysts expect from Neuropace next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $99.26M, with estimates from $91.60M to $101.10M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $120.48M, with estimates from $104.00M to $125.20M.
How many analysts cover NPCE?
10 analysts rate Neuropace stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NPCE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts